.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,935,602

« Back to Dashboard

Details for Patent: 5,935,602

Title: Dosage forms of risedronate
Abstract:The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical compostion which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epichelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower intestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which sometimes accompanies the oral administration of risedronate active ingredients.
Inventor(s): Dansereau; Richard John (Sherburne, NY), Mosher; Russell Youker (Norwich, NY), Axelrod; Douglas Wayne (Norwich, NY), Sietsema; William Kendall (Norwich, NY)
Assignee: The Procter & Gamble Company (Cincinnati, OH)
Filing Date:Mar 12, 1997
Application Number:08/820,430
Claims:1. A process for making a tablet containing risedronate; or a pharmaceutically acceptable salt thereof, comprising the step of:

a) mixing the risedronate with:

a filler; a viscosity agent; and optionally one or more additional ingredients selected from the group consisting of: buffer systems, flavoring agents, plasticizers, resins, solvents, co-solvents, surfactants, sweeteners and preservatives;

b) adding a lubricant; and

c) compressing the resulting mixture into tablet form.

2. The process of claim 1 wherein the filler is selected from the group consisting of lactose, sucrose, malodextrin and microcrystalline cellulose, or mixtures thereof.

3. The process according to claim 1 wherein the viscosity agent is selected from the group consisting of methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, carbomer, povidone, acacia, guar gum, xanthan gum and tragacanth, or mixtures thereof.

4. The process according to claim 1 wherein the viscosity agent is selected from the group consisting of methylcellulose, carbomer, xanthan gum, guar gum, povidone and sodium carboxymethylcellulose, or mixtures thereof.

5. The process according to claim 1 wherein the lubricant is selected from the group consisting of magnesium stearate, stearic acid, and talc, or mixtures thereof.

6. The process according to claim 3 wherein the lubricant is magnesium stearate and/or talc.

7. The process according to claim 2 wherein the filler is microcrystalline cellulose and/or lactose.

8. The process according to claim 2 wherein the viscosity agent is selected from the group consisting of methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, carbomer, povidone, acacia, guar gum, xanthan gum, tragacanth, or mixtures thereof.

9. The process according to claim 3 wherein the viscosity agent is selected from the group consisting of methylcellulose, carbomer, xanthan gum, guar gum, povidone and sodium carboxymethylcellulose, or mixtures thereof.

10. The process according to claim 2 wherein the lubricant is selected from the group consisting of magnesium stearate, stearic acid, talc, or mixtures thereof.

11. The process according to claim 3 wherein the lubricant is magnesium stearate and/or talc.

12. The process according to claim 7 wherein the viscosity agent is selected from the group consisting of methylcellulose, carbomer, xanthan gum, guar gum, povidone, sodium carboxymethylcellulose, or mixtures thereof.

13. The process according to claim 11 wherein the lubricant is magnesium stearate and/or talc.

14. A process for making a tablet containing risedronate or a pharmaceutically acceptable salt thereof; comprising the steps of:

a) mixing the risedronate with microcrystalline cellulose; followed by the addition of lactose and crospovidone; until a uniform mixture is formed;

b) adding magnesium stearate to the mixture until lubrication is achieved; and

c) compressing the mixture to form a tablet.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc